Table 4.
Multivariable Cox regression analyses overall survival in patients diagnosed between 2015 and 2016 (n = 735a)
| Patients no. | Median OS (months) | Univariable | Multivariable | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95%CI HR | P value | HR | 95%CI HR | P value | ||||
| Sex | |||||||||
| Female | 161 | 6.1 | Ref | Ref | |||||
| Male | 574 | 7.6 | 0.94 | 0.79–1.13 | 0.520 | 0.98 | 0.80–1.19 | 0.804 | |
| Age (years) | |||||||||
| < 50 | 228 | 7.6 | Ref | Ref | |||||
| 50–64 | 282 | 7.3 | 1.02 | 0.85–1.22 | 0.833 | 1.05 | 0.87–1.27 | 0.641 | |
| 65–79 | 207 | 6.5 | 1.00 | 0.82–1.22 | 0.988 | 1.04 | 0.84–1.28 | 0.754 | |
| ≥ 80 | 18 | 5.8 | 1.33 | 0.82–2.16 | 0.245 | 1.20 | 0.72–1.99 | 0.477 | |
| Performance status | |||||||||
| 0 or 1 | 459 | 7.8 | Ref | Ref | |||||
| ≥ 2 | 65 | 3.4 | 1.78 | 1.37–2.32 | < 0.001 | 1.75 | 1.34–2.30 | < 0.001 | |
| Unknown | 211 | 6.0 | 1.20 | 1.02–1.42 | 0.033 | 1.19 | 1.00–1.42 | 0.047 | |
| Number of comorbidities | |||||||||
| 0 | 225 | 7.6 | Ref | Ref | |||||
| 1 | 205 | 7.2 | 0.93 | 0.76–1.13 | 0.474 | 0.91 | 0.74–1.11 | 0.351 | |
| ≥ 2 | 246 | 6.2 | 1.18 | 0.98–1.42 | 0.088 | 1.15 | 0.94–1.41 | 0.165 | |
| Unknown | 59 | 8.9 | 0.89 | 0.66–1.19 | 0.427 | 0.83 | 0.61–1.13 | 0.231 | |
| Primary tumor location | |||||||||
| Esophagus | 344 | 7.3 | 0.94 | 0.79–1.11 | 0.431 | 1.05 | 0.85–1.29 | 0.659 | |
| GEJ/cardia | 143 | 7.8 | 0.85 | 0.69–1.05 | 0.138 | 0.96 | 0.76–1.21 | 0.703 | |
| Stomach | 248 | 6.5 | Ref | Ref | |||||
| Tumor histology | |||||||||
| Adenocarcinoma NOS | 178 | 7.3 | Ref | Ref | |||||
| Intestinal-type adenocarcinoma | 350 | 8.0 | 1.00 | 0.83–1.21 | 0.992 | 0.95 | 0.77–1.19 | 0.671 | |
| Diffuse type adenocarcinoma | 169 | 6.0 | 1.31 | 1.05–1.64 | 0.015 | 1.33 | 1.01–1.74 | 0.040 | |
| Indeterminate type adenocarcinoma | 38 | 5.9 | 1.36 | 0.95–1.94 | 0.096 | 1.26 | 0.86–1.84 | 0.243 | |
| Number of metastatic locations | |||||||||
| 1 | 389 | 7.7 | Ref | Ref | |||||
| ≥ 2 | 346 | 6.6 | 1.22 | 1.05–1.42 | 0.010 | 1.25 | 1.07–1.46 | 0.005 | |
| Year of diagnosis | |||||||||
| 2015 | 429 | 6.7 | Ref | Ref | |||||
| 2016 | 306 | 7.7 | 0.88 | 0.76–1.03 | 0.107 | 0.95 | 0.79–1.14 | 0.580 | |
| Hospital volumeb | |||||||||
| < 13 patients | 70 | 5.2 | 1.28 | 0.97–1.67 | 0.081 | 1.26 | 0.95–1.67 | 0.104 | |
| 13–31 patients | 151 | 6.4 | 1.26 | 1.03–1.54 | 0.026 | 1.19 | 0.96–1.47 | 0.135 | |
| 32–76 patients | 220 | 7.0 | 1.11 | 0.93–1.33 | 0.247 | 1.04 | 0.86–1.25 | 0.669 | |
| > 76 patients | 294 | 7.9 | Ref | Ref | |||||
| HER2 status | |||||||||
| HER2 not tested | 148 | 5.6 | Ref | Ref | |||||
| HER2 tested, HER2 negative | 392 | 7.4 | 0.77 | 0.64–0.94 | 0.010 | 0.81 | 0.66–1.00 | 0.040 | |
| HER2 tested, HER2 positive | 118 | 8.8 | 0.62 | 0.48–0.80 | < 0.001 | 0.66 | 0.49–0.85 | 0.002 | |
| HER2 tested, HER2 unknown | 77 | 7.9 | 0.81 | 0.61–1.07 | 0.136 | 0.81 | 0.60–1.06 | 0.165 | |
Multivariable Cox regression analyses for overall survival in patients diagnosed in 2015 and 2016
OS overall survival, HR hazard ratio, CI confidence interval, GEJ gastroesophageal junction, NOS not otherwise specified
aPatients in whom HER2 was determined after 31 days of start of systemic treatment (N = 27) were excluded to prevent an immortal time bias
bHospitals are categorized in quartiles based on the hospital volume of all gastroesophageal cancer patients treated with systemic therapy in 2015 and 2016